Chemical inhibitors of PUS7L can exert their inhibitory effects through a variety of mechanisms that impact the protein's function in post-translational RNA modification. The compound 6-Diazo-5-oxo-L-norleucine, a glutamine antagonist, can impede glutamine-dependent enzymes that may be crucial for the activity of PUS7L. The nucleotide analog 5-Fluorouracil is incorporated into RNA, which can disrupt RNA modifications involving PUS7L. Methotrexate, by limiting dihydrofolate reductase, reduces tetrahydrofolate levels, thus affecting nucleotide synthesis that is essential for PUS7L's function in RNA modification. Cycloheximide's interference with the translocation step in protein elongation can result in a deficiency of necessary protein factors for PUS7L's functioning. Puromycin, which mimics aminoacyl-tRNA, can reduce the synthesis of proteins that are integral to PUS7L's role, leading to inhibition of PUS7L. Actinomycin D inhibits RNA synthesis by intercalating into DNA, thus potentially reducing the availability of RNA substrates for PUS7L. Alpha-amanitin, a potent inhibitor of RNA polymerase II, can decrease RNA synthesis, thereby limiting the RNA substrates required for PUS7L's action.
Furthermore, Rifampicin targets the beta subunit of RNA polymerase to inhibit RNA transcription, which can reduce RNA availability for PUS7L. Tunicamycin prevents N-linked glycosylation, potentially affecting the glycosylation status of proteins that interact with PUS7L or its RNA substrates, thereby inhibiting PUS7L. Anisomycin's inhibition of peptidyl transferase activity on ribosomes can indirectly inhibit PUS7L by disrupting the synthesis of essential proteins for PUS7L's activity. Chloramphenicol, though it mainly targets bacteria, can inhibit PUS7L by affecting protein synthesis in eukaryotic mitochondria, which is vital for PUS7L's function. Lastly, Emetine impedes protein synthesis by blocking ribosomal movement along mRNA, which can lead to a reduction in available proteins necessary for PUS7L's RNA modification functions, resulting in the inhibition of PUS7L. Each chemical, through its distinct mechanism, can inhibit the functional activity of PUS7L by limiting the production or availability of crucial proteins and RNA substrates necessary for PUS7L's role in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
6-Diazo-5-oxo-L-norleucine | 157-03-9 | sc-227078 sc-227078A sc-227078B sc-227078C | 5 mg 25 mg 100 mg 250 mg | $88.00 $291.00 $926.00 $2195.00 | ||
This chemical is a glutamine antagonist that can inhibit glutamine-dependent enzymes, which may be required for the post-translational modification of PUS7L, thereby inhibiting its function. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
As a nucleotide analog, this compound can be incorporated into RNA molecules, potentially disrupting the RNA modification process that PUS7L is involved in, leading to the inhibition of PUS7L's function. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
By inhibiting dihydrofolate reductase, Methotrexate leads to reduced levels of tetrahydrofolate and consequently impacts the biosynthesis of nucleotides required for RNA modifications where PUS7L is active. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
This chemical inhibits eukaryotic protein synthesis by interfering with the translocation step in protein elongation. Since PUS7L functions in post-transcriptional RNA modification, inhibition of protein synthesis can indirectly inhibit PUS7L's function due to a lack of necessary protein factors. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during translation by acting as an analog to aminoacyl-tRNA. This could decrease the availability of proteins needed for PUS7L to exert its function, thereby inhibiting PUS7L. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
This compound intercalates into DNA and prevents RNA synthesis by RNA polymerase, which could reduce the availability of RNA substrates for modification by PUS7L, functionally inhibiting it. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
A potent inhibitor of RNA polymerase II, alpha-amanitin can reduce RNA synthesis, thereby decreasing the substrate pool necessary for PUS7L's RNA modification activity, leading to functional inhibition. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
It binds to the beta subunit of RNA polymerase, inhibiting RNA transcription. This reduction in RNA can limit the substrate availability for PUS7L, thus inhibiting its function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
An inhibitor of N-linked glycosylation, which could affect the glycosylation status of proteins interacting with PUS7L or its RNA substrates, potentially inhibiting PUS7L's function. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
This chemical inhibits peptidyl transferase activity on the ribosome, which can indirectly inhibit PUS7L by disrupting the synthesis of proteins that are essential for PUS7L's activity. | ||||||